Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

NCT07531095 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: ZL-1310
DRUG: Tarlatamab
DRUG: Durvalumab

Sponsor

Amgen